HEALTH.2013.0-1
HEALTH.2013.0-1
16 projects · €84,280,958 total EU contribution (project-level) · 72 participating organizations · 18 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€84,280,958
Countries active
Participant organizations by country (headquarters in CORDIS).
- Germany (12)
- Netherlands (11)
- UK (10)
- SE (8)
- France (7)
- BE (3)
- FI (3)
- Italy (3)
- CH (2)
- DK (2)
- Spain (2)
- HU (2)
- AT (1)
- EL (1)
- IL (1)
- IS (1)
- NO (1)
- PT (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- Leiden University Medical Center4 projects · NL
- ARTTIC2 projects · FR
- PRESENS PRECISION SENSING GMBH2 projects · DE
- 3H Biomedical AB1 projects · SE
- Aber Instruments Lim1 projects · UK
- AMC1 projects · NL
- MOLMED SPA1 projects · IT
- AN1 projects · UK
- AIM1 projects · FR
- astraia1 projects · DE
- Athera1 projects · SE
- AVANTEA1 projects · IT
Projects
Page 1 of 2
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Cancer Responsiveness Monitoring based on Resistance mutations in CTCs CAREMORE · 601760 | FP7 | €5,127,632 | €7,224,029 | Details |
Macroencapsulated Porcine Pancreatic Islets to cure Diabetes Mellitus type 1/2 XENOISLET · 601827 | FP7 | €5,037,148 | €6,396,947 | Details |
Consortium for Products across Europe in Duchenne Muscular Dystrophy SCOPE-DMD · 601573 | FP7 | €5,999,210 | €21,358,069 | Details |
High Efficient, Single-Use-Bioreactor simulating mammalian tissue conditions for expression and proliferation HESUB · 601700 | FP7 | €5,752,150 | €7,592,834 | Details |
bioREACtor for stem cell tHerapy REACH · 601869 | FP7 | €5,012,127 | €6,790,995 | Details |
Mutanome Engineered RNA Immuno-Therapy MERIT · 601939 | FP7 | €5,964,250 | €7,794,995 | Details |
Combined Multi-marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention ASPRE · 601852 | FP7 | €5,839,800 | €7,556,141 | Details |
Translation of novel Biomarkers for Bladder Cancer for clinical outcome prediction TRANSBIOBC · 601933 | FP7 | €3,260,359 | €4,181,539 | Details |
Testing and validation of bispecific antibody combinations targeting treatment-resistant cancer stem cells using organoid-based screening tools: a new drug discovery paradigm SUPPRESSTEM · 601876 | FP7 | €5,953,319 | €7,756,658 | Details |
Donor T Cells for Immune Control T-CONTROL · 601722 | FP7 | €5,682,536 | €7,437,856 | Details |